Off-Label Uses of Anti-TNF Therapy in Three Frequent Disorders: Behçet's Disease, Sarcoidosis, and Noninfectious Uveitis
Tumoral necrosis factor α plays a central role in both the inflammatory response and that of the immune system. Thus, its blockade with the so-called anti-TNF agents (infliximab, etanercept, adalimumab, certolizumab pegol, and golimumab) has turned into the most important tool in the management of a...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Book |
| Published: |
Hindawi Limited,
2013-01-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_10cdc6fd9e7a4d4dba19e39bdb295358 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Daniel Sánchez-Cano |e author |
| 700 | 1 | 0 | |a José Luis Callejas-Rubio |e author |
| 700 | 1 | 0 | |a Ricardo Ruiz-Villaverde |e author |
| 700 | 1 | 0 | |a Raquel Ríos-Fernández |e author |
| 700 | 1 | 0 | |a Norberto Ortego-Centeno |e author |
| 245 | 0 | 0 | |a Off-Label Uses of Anti-TNF Therapy in Three Frequent Disorders: Behçet's Disease, Sarcoidosis, and Noninfectious Uveitis |
| 260 | |b Hindawi Limited, |c 2013-01-01T00:00:00Z. | ||
| 500 | |a 0962-9351 | ||
| 500 | |a 1466-1861 | ||
| 500 | |a 10.1155/2013/286857 | ||
| 520 | |a Tumoral necrosis factor α plays a central role in both the inflammatory response and that of the immune system. Thus, its blockade with the so-called anti-TNF agents (infliximab, etanercept, adalimumab, certolizumab pegol, and golimumab) has turned into the most important tool in the management of a variety of disorders, such as rheumatoid arthritis, spondyloarthropatties, inflammatory bowel disease, and psoriasis. Nonetheless, theoretically, some other autoimmune disorders may benefit from these agents. Our aim is to review these off-label uses of anti-TNF blockers in three common conditions: Behçet's disease, sarcoidosis, and noninfectious uveitis. Due to the insufficient number of adequate clinical trials and consequently to their lower prevalence compared to other immune disorders, this review is mainly based on case reports and case series. | ||
| 546 | |a EN | ||
| 690 | |a Pathology | ||
| 690 | |a RB1-214 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Mediators of Inflammation, Vol 2013 (2013) | |
| 787 | 0 | |n http://dx.doi.org/10.1155/2013/286857 | |
| 787 | 0 | |n https://doaj.org/toc/0962-9351 | |
| 787 | 0 | |n https://doaj.org/toc/1466-1861 | |
| 856 | 4 | 1 | |u https://doaj.org/article/10cdc6fd9e7a4d4dba19e39bdb295358 |z Connect to this object online. |